ChiCTR2600122083 版本V1.0 版本创建时间2026/04/08 17:41:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600122083 

最近更新日期:

Date of Last Refreshed on:

2026-04-08 17:41:49 

注册时间:

Date of Registration:

2026-04-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

一项评价免缝合眼用水凝胶粘用于眼表组织粘附治疗的有效性与安全性的单中心临床研究

Public title:

A Single-Center Clinical Study on the Efficacy and Safety of a Sutureless Ophthalmic Hydrogel Adhesive for Ocular Surface Tissue Adhesion.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

一项评价免缝合眼用水凝胶粘用于眼表组织粘附治疗的有效性与安全性的单中心临床研究

Scientific title:

A Single-Center Clinical Study on the Efficacy and Safety of a Sutureless Ophthalmic Hydrogel Adhesive for Ocular Surface Tissue Adhesion.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李素霞 

研究负责人:

史伟云 

Applicant:

Suxia Li 

Study leader:

Weiyun Shi 

申请注册联系人电话:

Applicant telephone:

+86 81276101

研究负责人电话:

Study leader's
telephone:

+86 531 8127 6002

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lsuxiasusu@163.com

研究负责人电子邮件:

Study leader's E-mail:

weiyunshi@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市槐荫区经四路372号

研究负责人通讯地址:

山东省济南市槐荫区经四路372号

Applicant address:

372 Jingsi Road, Huaiyin District, Jinan City, Shandong Province, China

Study leader's address:

372 Jingsi Road, Huaiyin District, Jinan City, Shandong Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第一医科大学附属眼科医院

Applicant's institution:

Eye Hospital of Shandong First Medical University

研究负责人所在单位:

山东第一医科大学附属眼科医院

Affiliation of the Leader:

Eye Hospital of Shandong First Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SDSYKYY202510-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东省眼科医院伦理委员会

Name of the ethic committee:

Shandong Eye Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-10 00:00:00

伦理委员会联系人:

刘金辉

Contact Name of the ethic committee:

Jinhui Liu

伦理委员会联系地址:

山东省济南市槐荫区经四路372号

Contact Address of the ethic committee:

372 Jingsi Road, Huaiyin District, Jinan City, Shandong Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 531 8127 6101

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东第一医科大学附属眼科医院

Primary sponsor:

Eye Hospital of Shandong First Medical University

研究实施负责(组长)单位地址:

山东省济南市经四路372号

Primary sponsor's address:

No.372, Jingsi Road, Jinan City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong Province

City:

单位(医院):

山东第一医科大学附属眼科医院

具体地址:

山东省济南市槐荫区经四路372号

Institution
hospital:

Eye Hospital of Shandong First Medical University

Address:

No.372, Jingsi Road, Jinan City, Shandong Province

经费或物资来源:

研究者自筹经费

Source(s) of funding:

Researchers self-funded

研究疾病:

眼表疾病(如翼状胬肉、角膜溃疡、眼表烧伤等)  

Target disease:

Ocular surface diseases, including pterygium, corneal ulcer, and ocular surface burns.

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

以需进行眼表组织粘附手术治疗的患者为研究对象,观察使用免缝合眼用水凝胶实现眼表组织粘附的安全性和有效性  

Objectives of Study:

This study enrolled patients requiring ocular surface tissue adhesion surgery to evaluate the safety and efficacy of using a sutureless ophthalmic hydrogel adhesive for tissue adhesion.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 因眼表疾病(如翼状胬肉、角膜溃疡、眼表烧伤、假性胬肉等)需行结膜瓣粘附、羊膜移植术、角膜移植手术的患者。 2. 同意获取时年龄在18岁以上、85岁以下(性别不限)。 3. 能够从本人处获取书面同意,自愿参加本研究的患者。 4. 无严重全身器质性疾病,如严重心、肝、肾疾病及恶性肿瘤等。

Inclusion criteria

1. Patients for whom surgical adhesion of ocular surface tissue is indicated due to conditions such as pterygium, corneal ulcer, ocular surface burn, or pseudopterygium, involving procedures like conjunctival flap adhesion, amniotic membrane transplantation, or keratoplasty. 2. Aged 18–85 years (any gender) at the time of consent. 3. Ability to provide written informed consent for voluntary participation in the study. 4. Absence of severe systemic organic diseases, including but not limited to severe cardiac, hepatic, renal disorders, and malignant tumors.

排除标准:

1. 对免缝合眼用水凝胶成分(如脱细胞猪角膜基质、甲基丙烯酰化明胶等)或围手术期及术后观察期间处方药物(麻醉药、抗生素、类固醇制剂等)有过敏史的患者。 2. 患有全身性感染症(细菌、真菌、HBV、HCV等病毒阳性者等)的患者。 3. 血糖控制不佳的糖尿病患者(HbA1C 8.0%以上)。 4. 孕妇及可能怀孕、或计划在本临床研究期间怀孕的女性。 5. 同意获取前1个月内参加过其他临床试验或临床研究的患者。 6. 其他因合并症等被认为不适合实施本临床研究的患者。

Exclusion criteria:

1. Patients with a known allergy or hypersensitivity to any component of the sutureless ophthalmic hydrogel (e.g., decellularized porcine corneal stroma, gelatin methacryloyl) or to any peri-/post-operative medication prescribed (e.g., anesthetics, antibiotics, steroids). 2. Patients with active systemic infection (e.g., bacterial, fungal, or viral infections such as HBV or HCV positivity). 3. Diabetic patients with poor glycemic control (HbA1c > 8.0%). 4. Pregnant or lactating women, women of childbearing potential not using adequate contraception, or women planning to become pregnant during the study period. 5. Patients who have participated in any other clinical trial or investigational study within one month prior to the screening visit. 6. Patients deemed by the investigator to be unsuitable for participation in this clinical study due to other comorbidities or reasons.

研究实施时间:

Study execute time:

From 2026-03-01 00:00:00 To 2027-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-08 00:00:00 To 2027-03-01 00:00:00

干预措施:

Interventions:

组别:

水凝胶粘附组

样本量:

30

Group:

Hydrogel Adhesion Group

Sample size:

干预措施:

使用水凝胶进行眼表组织粘附

干预措施代码:

Intervention:

Adhering ocular surface tissue with hydrogel.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东第一医科大学附属眼科医院  

单位级别:

三甲 

Institution
hospital:

Shandong First Medical University Affiliated Eye Hospital/Shandong Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼表刺激症状评分

指标类型:

主要指标

Outcome:

Ocular Irritation Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

结膜充血评分

指标类型:

主要指标

Outcome:

Conjunctival Redness Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼压

指标类型:

主要指标

Outcome:

IOP(mmHg)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

结膜瓣粘附情况

指标类型:

次要指标

Outcome:

Condition of Conjunctival Flap Adhesion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视力

指标类型:

次要指标

Outcome:

Vision

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录和电子采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Medical Records and Electronic Data Collection

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-08 17:41:49